Profile data is unavailable for this security.
About the company
Essex Bio-Technology Ltd is an investment holding company mainly engaged in the production and sale of biopharmaceuticals for the treatment of body surface trauma and eye injuries. The Company operates its business through three segments. The Surgical segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifuji spray, Beifuji lyophilized powder, Beifuxin gel and others. The Ophthalmology segment is engaged in the development, manufacture and sale of Beifuji series products such as Beifushu eye drops, Beifushu eye gel, Beifushu single-dose eye drops and others. The Provision of Services segment is engaged in the provision of healthtech e-platform related medical services.
- Revenue in HKD (TTM)1.73bn
- Net income in HKD313.18m
- Incorporated2000
- Employees1.43k
- LocationEssex Bio-Technology LtdRoom 2818,Chn Mrchnts Twr,Shn Tk Ctr168-200 Connaught Road CentralCentral Hong KongHKG
- Phone+852 25877838
- Fax+852 25877363
- Websitehttp://www.essexbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Biostar Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 1.37bn | 147.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.85 | -- | 24.19 | -- | -- | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.26bn | 199.86m | 1.77bn | 1.12k | 8.89 | 0.4741 | 6.00 | 1.41 | 0.1327 | 0.1327 | 0.8371 | 2.49 | 0.2809 | 2.47 | 7.96 | 1,065,846.00 | 4.36 | 10.98 | 5.07 | 13.75 | 45.76 | 55.52 | 15.53 | 32.76 | 4.21 | -- | 0.0028 | 31.01 | -7.89 | 2.22 | 73.29 | 17.20 | 17.13 | 2.69 |
| Cutia Therapeutics | 283.52m | -534.89m | 1.87bn | 298.00 | -- | 1.93 | -- | 6.60 | -1.70 | -1.70 | 0.9023 | 2.67 | 0.1908 | 2.55 | 5.57 | 851,414.80 | -36.00 | -- | -44.42 | -- | 34.92 | -- | -188.66 | -- | 2.92 | -- | 0.2774 | -- | 103.17 | -- | 77.91 | -- | -- | -- |
| Zhaoke Ophthalmology Ltd | 40.05m | -315.22m | 1.90bn | 270.00 | -- | 0.9779 | -- | 47.34 | -0.5698 | -0.5698 | 0.0725 | 3.54 | 0.0159 | 1.38 | 9.25 | 136,211.20 | -12.50 | -38.02 | -14.65 | -41.79 | 49.28 | -- | -787.13 | -4,412.89 | 4.36 | -29.83 | 0.1373 | -- | 269.73 | -- | 38.32 | -- | 18.80 | -- |
| Jbm (Healthcare) Ltd | 812.98m | 216.39m | 2.29bn | 412.00 | 10.46 | 2.12 | 8.23 | 2.81 | 0.2657 | 0.2657 | 0.9984 | 1.31 | 0.5111 | 3.76 | 5.05 | 2,913,918.00 | 14.09 | 6.57 | 17.00 | 7.83 | 56.76 | 47.82 | 27.56 | 16.60 | 2.41 | -- | 0.2486 | 53.40 | 20.65 | 15.44 | 51.20 | 36.90 | 35.96 | -- |
| Hangzhou Jiuyuan Genetic Biopharm Co Ltd | 1.48bn | 139.79m | 2.32bn | 1.63k | 14.82 | 1.30 | 12.42 | 1.57 | 0.6472 | 0.6472 | 7.24 | 7.37 | 0.7509 | 1.55 | 2.17 | 959,578.90 | 7.10 | -- | 8.88 | -- | 81.67 | -- | 9.45 | -- | 4.03 | 46.31 | 0.1058 | -- | 6.35 | -- | 15.72 | -- | -- | -- |
| Golden Throat Holdings Group Co Ltd | 1.11bn | 303.66m | 2.32bn | 842.00 | 7.64 | 1.70 | 6.80 | 2.09 | 0.4107 | 0.4107 | 1.50 | 1.85 | 0.467 | 2.29 | 5.32 | 1,269,576.00 | 12.78 | 11.71 | 21.02 | 16.75 | 76.42 | 73.08 | 27.37 | 25.87 | 1.73 | 21.95 | 0.3616 | 94.67 | 23.26 | 8.25 | 27.37 | 13.71 | -12.27 | 34.38 |
| Essex Bio-Technology Ltd | 1.73bn | 313.18m | 2.51bn | 1.43k | 8.04 | 1.10 | 6.78 | 1.45 | 0.5508 | 0.5508 | 3.05 | 4.01 | 0.5596 | 2.96 | 2.84 | 1,196,360.00 | 10.10 | 10.28 | 13.56 | 13.62 | 89.50 | 87.73 | 18.05 | 18.70 | 1.82 | -- | 0.1135 | 17.49 | -3.87 | 5.47 | 11.61 | 0.3101 | -7.47 | 7.14 |
| Jacobson Pharma Corporation Ltd | 1.53bn | 302.58m | 2.54bn | 1.79k | 8.36 | 1.14 | 5.63 | 1.66 | 0.1519 | 0.1519 | 0.7698 | 1.12 | 0.4299 | 2.54 | 9.06 | 876,757.00 | 8.48 | 4.83 | 10.29 | 6.17 | 44.30 | 41.26 | 19.73 | 14.85 | 0.9023 | 10.21 | 0.286 | 57.09 | 7.43 | 0.0691 | 43.09 | 7.05 | 24.09 | 14.87 |
| SinoMab Bioscience Ltd | 0.00 | -163.48m | 2.62bn | 61.00 | -- | 8.26 | -- | -- | -0.151 | -0.151 | 0.00 | 0.2288 | 0.00 | -- | -- | 0.00 | -18.46 | -22.26 | -24.62 | -25.68 | -- | -- | -- | -3,832.94 | -- | -7.82 | 0.6265 | -- | 48.42 | -- | 23.85 | -- | -0.376 | -- |
Data as of Feb 13 2026. Currency figures normalised to Essex Bio-Technology Ltd's reporting currency: Hong Kong Dollar HKD
1.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 4.47m | 0.79% |
| Pheim Asset Management Sdn. Bhd.as of 30 Jun 2025 | 2.48m | 0.44% |
| Lacuna Verm�gen GmbHas of 31 Dec 2024 | 680.00k | 0.12% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 294.00k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 203.23k | 0.04% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Jan 2026 | 97.00k | 0.02% |
| DFA Australia Ltd.as of 31 Dec 2025 | 75.13k | 0.01% |
| RAM Active Investments SAas of 30 Jun 2025 | 64.00k | 0.01% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
